Project Grant K23AI193258
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $189K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Baylor College of Medicine $752,172 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a mechanistic study of an RNA translocase via integrative multi-resolution approach. The research investigates how mycobacteria persist in the host by examining a conserved bifunctional RNA helicase and nuclease enzyme found across mycobacterium species. The enzyme is thought to promote...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $419,082 on September 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to mentor multidisciplinary research on multidrug-resistant tuberculosis adherence and emergent drug resistance. The award funds mentorship-driven research to train a new cadre of clinical investigators in patient-oriented research addressing multidrug-resistant TB...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $315,700 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research elucidating spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis stress response and replication heterogeneity. The project investigates how spatial organization of tuberculosis lesions in the lung...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Boston University $245,250 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the phenotypes and genesis of arginase 1-positive myeloid cells in pulmonary tuberculosis using a genetic mouse model of chronic TB. The research uses the B6.SST1S mouse model, which develops human-like organized necrotic granulomas after aerosol, intravenous, or subcutaneous infection...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $194,400 on September 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research career development program investigating antibody-dependent innate effector function in tuberculosis disease progression among HIV co-infected individuals. The research will apply expanded effector functional profiling to evaluate how HIV alters the breadth...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $281,500 on August 3, 2026, to investigate human neutralizing autoantibodies to interferon-gamma underlying mycobacterial diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research addresses the hypothesis that tuberculosis in some patients is caused by interferon-gamma autoantibodies with lower titer and/or lower affinity than those...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, San Francisco $358,032 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a systematic evaluation of post-tuberculosis lung disease (PTLD) and its relationship to HIV status. The project, titled "The Sequelae TB Study," will comprehensively characterize PTLD among a prospective cohort of TB survivors in Lusaka, Zambia. The...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $795,622 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mycobacterium tuberculosis impact on HIV reservoir clearance. The research examines how tuberculosis disease affects HIV-1 latent reservoirs in people living with HIV. The study will recruit 200 people with HIV, half with active tuberculosis disease, and follow them for up to 18 months....
- The National Institute of Allergy and Infectious Diseases awarded $1.59 million to the University of Colorado-Denver under Project Grant R01AI187511 on September 17, 2025, to support research integrating genomic architecture and tuberculosis immunity in Africa under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research generates population-level genetic data (HLA, KIR, and SNP array) on 5,000 case/control samples from multi-ancestry individuals in South Africa's...